
|Videos|December 27, 2022
RCC Trial Review: COSMIC-313
Author(s)Rana R. McKay, MD
Discussion centered around the unmet needs that the COSMIC-313 trial aims to address, as well as information about included patient populations, study design, and recent conference data.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
3
Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm
4
First Patients Dosed With TLX597-Tx in Trial for mHSPC
5





























